| Description | TCV-309 is an inhibitor of platelet activating factor (PAF). TCV-309 reduces graft PMN infiltration and enhances early function of 24-hour-preserved rat kidneys with long warm ischemia. TCV-309 attenuates the priming effects of bronchoalveolar macrophages in cerulein-induced pancreatitis rats. TCV-309 inhibits leukocyte accumulation and protects against splanchnic artery occlusion shock. |
| Synonyms | TCV309 |
| molecular weight | 656.52 |
| Molecular formula | C30H34BrN5O7 |
| CAS | 131311-25-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Poeze M, Froon AH, Ramsay G, Buurman WA, Greve JW. Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II trial. TCV-309 Septic Shock Study Group. Shock. 2000 Oct;14(4):421-8. PubMed PMID: 11049104. 2. Yamaguchi Y, Matsumura F, Liang J, Okabe K, Matsuda T, Ohshiro H, Ishihara K, Akizuki E, Yamada S, Ogawa M. Platelet-activating factor antagonist (TCV-309) attenuates the priming effects of bronchoalveolar macrophages in cerulein-induced pancreatitis rats. Pancreas. 1999 May;18(4):355-63. PubMed PMID: 10231840. 3. Qayumi AK, English JE, Duncan S, Ansley DM, Pearson B, Nikbakht-Sangari M, Sammartino C, Fradet G. Extended lung preservation with platelet-activating factor-antagonist TCV-309 in combination with prostaglandin E1. J Heart Lung Transplant. 1997 Sep;16(9):946-55. PubMed PMID: 9322146. 4. Yin M, Buurman WA, Daemen JW, Kootstra G. The PAF antagonist TCV-309 reduces graft PMN infiltration and enhances early function of 24-hour-preserved rat kidneys with long warm ischemia. Transplantation. 1996 May 27;61(10):1443-6. PubMed PMID: 8633367. |